These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. Akhtar S; Maghfoor I J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496 [No Abstract] [Full Text] [Related]
3. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma]. Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888 [TBL] [Abstract][Full Text] [Related]
4. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. King KM; Younes A Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023 [TBL] [Abstract][Full Text] [Related]
5. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Molina A Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705 [TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy for low-grade lymphomas: has the time come? Cartron G; Solal-Céligny P Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565 [TBL] [Abstract][Full Text] [Related]
8. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Traullé C; Coiffier BB Future Oncol; 2005 Jun; 1(3):297-306. PubMed ID: 16556002 [TBL] [Abstract][Full Text] [Related]
14. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy]. Korolenko VO; Gershanovich ML; Tikhonova VV Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764 [No Abstract] [Full Text] [Related]
15. ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma. Williams ME Curr Hematol Rep; 2004 Nov; 3(6):395-6. PubMed ID: 15496271 [No Abstract] [Full Text] [Related]
16. Rituximab (Rituxan/MabThera): the first decade (1993-2003). Grillo-López AJ Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Tobinai K Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: moving targets. van Oers MH Neth J Med; 2009 Sep; 67(8):309-10. PubMed ID: 19767656 [No Abstract] [Full Text] [Related]
19. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy. Tsutsumi Y; Ichiki K; Shiratori S; Kawamura T; Tanaka J; Asaka M; Imamura M; Masauzi N Int J Lab Hematol; 2009 Aug; 31(4):468-70. PubMed ID: 18294236 [No Abstract] [Full Text] [Related]
20. Non-Hodgkin's lymphoma in the elderly. Part 1: Overview and treatment of follicular lymphoma. Morrison VA Oncology (Williston Park); 2007 Aug; 21(9):1104-10. PubMed ID: 17910313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]